Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(40.0%)
N/A
2(40.0%)
Phase 1
1(20.0%)
5Total
Phase 2(2)
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04983745Phase 2Unknown

Niraparib and Dostarlimab in HRD Solid Tumors

Role: lead

NCT03812393Phase 2Unknown

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

Role: lead

NCT04331678Not ApplicableCompleted

Evaluation of a Mobile App to Promote Social Support for Oncology Patients

Role: lead

NCT03592771Not ApplicableCompleted

THRIVE Breast Cancer App Study

Role: collaborator

NCT03088176Phase 1Unknown

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Role: lead

All 5 trials loaded